|
Bieżący numer
Archiwum
Filmy
Artykuły w druku
O czasopiśmie
Suplementy
Rada naukowa
Recenzenci
Bazy indeksacyjne
Prenumerata
Kontakt
Zasady publikacji prac
Opłaty publikacyjne
Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
|
Artykuł przeglądowy
Current insights into the diagnosis and management of melanocytic choroidal tumors: a short review
Emilia Zwolińska
1
,
Lazaros Konstantinidis
2
,
Iwona Rospond-Kubiak
1
KLINIKA OCZNA 2025, 127, 3:
Data publikacji online: 2025/08/22
Plik artykułu:
- KO-00503_EN.pdf
[1.94 MB]
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye 2017; 31: 241-257. 2.
Singh AD, Kalyani P, Topham A. Estimating the Risk of Malignant Transformation of a Choroidal Nevus. Ophthalmology 2005; 112: 1784-1789. 3.
Papastefanou VP, Nogueira V, Hay G, et al. Choroidal naevi complicated by choroidal neovascular membrane and outer retinal tubulation. Br J Ophthalmol 2013; 97: 1014-1019. 4.
Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110: 245-250. 5.
Smidt‐Nielsen I, Bagger M, Heegaard S, et al. Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70‐year nationwide cohort. Acta Ophthalmol 2021; 99: e1474-e1482. 6.
Ng CH. Prevalence and Characteristics of Choroidal Nevi in an Asian vs White Population. Arch Ophthalmol 2009; 127: 314. 7.
Greenstein MB, Myers CE, Meuer SM, et al. Prevalence and Characteristics of Choroidal Nevi: The Multi-Ethnic Study of Atherosclerosis. Ophthalmology 2011; 118: 2468-2473. 8.
Jonas JB, You QS, Xu L, Wang YX. Choroidal Nevi in Adult Chinese. Ophthalmology 2008; 115: 1102-1102.e1. 9.
Sumich P. Choroidal Nevi in a White Population: The Blue Mountains Eye Study. Arch Ophthalmol 1998; 116: 645. 10.
Nangia V, Jonas JB, Agarwal S, Khare A, Lambat S, Panda-Jonas S. Choroidal nevi in adult Indians: The Central India Eye and Medical Study. Br J Ophthalmol 2012; 96: 1443.1-1444. 11.
Qiu M, Shields CL. Choroidal Nevus in the United States Adult Population. Ophthalmology 2015; 122: 2071-2083. 12.
Virgili G, Gatta G, Ciccolallo L, et al. Incidence of Uveal Melanoma in Europe. Ophthalmology 2007; 114: 2309-2315.e2. 13.
Raval V, Bellerive C, Singh AD, Gopinath B, Liew G, Mitchell P. Choroidal nevi in children: prevalence, age of onset, and progression. J AAPOS. 2021 Aug;25(4):225.e1-225.e6. 14.
Shields CL, Kaliki S, Arepalli S, et al. Uveal melanoma in children and teenagers. Saudi J Ophthalmol 2013; 27: 197-201. 15.
Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol 2015; 99: 1550-1553. 16.
Strickland D, Lee JAH. Melanomas of eye: stability of rates. Am J Epidemiol 1981; 113: 700-702. 17.
Stang A, Parkin DM, Ferlay J, Jöckel KH. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification: International Uveal Melanoma Incidence Trends. Int J Cancer 2005; 114: 114-123. 18.
Naumann G, Yanoff M, Zimmerman LE. Histogenesis of malignant melanomas of the uvea. I. Histopathologic characteristics of nevi of the choroid and ciliary body. Arch Ophthalmol 1966; 76: 784-796. 19.
Yanoff M, Zimmerman LE. Histogenesis of malignant melanomas of the uvea.II. Relationship of uveal nevi to malignant melanomas. Cancer 1967; 20: 493-507. 20.
Rietschel P, Panageas KS, Hanlon C, et al. Variates of Survival in Metastatic Uveal Melanoma. J Clin Oncol 2005; 23: 8076-8080. 21.
Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101: 38-44. 22.
Stålhammar G, Gill VT. The long-term prognosis of patients with untreated primary uveal melanoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2022; 172: 103652. 23.
Jouhi S, Jager MJ, De Geus SJR, et al. The Small Fatal Choroidal Melanoma Study. A Survey by the European Ophthalmic Oncology Group. Am J Ophthalmol 2019; 202: 100-108. 24.
Shields CL, Dalvin LA, Ancona-Lezama D, et al. Choroidal nevus imaging features in 3,806 cases and risk factors for transformation into melanoma in 2,355 cases. Retina 2019; 39: 1840-1851. 25.
Shields CL, Lally SE, Dalvin LA, et al. White paper on ophthalmic imaging for choroidal nevus identification and transformation into Melanoma 2021; 10: 1-10. 26.
Kubicka-Trzaska A, Starzycka M, Romanowska-Dixon B. Indocyanine Green Angiography in the Diagnosis of Small Choroidal Tumours. Ophthalmologica 2002; 216: 316-319. 27.
Yannuzzi LA. Indocyanine Green Angiography: A Perspective on Use in the Clinical Setting. Am J Ophthalmol 2011; 151: 745-751.e1. 28.
Shields CL, Shields JA, Kiratli H, et al. Risk Factors for Growth and Metastasis of Small Choroidal Melanocytic Lesions. Ophthalmology 1995; 102: 1351-1361. 29.
Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 2009; 127: 981-987. 30.
Factors Predictive of Growth and Treatment of Small Choroidal Melanoma: COMS Report No. 5. Arch Ophthalmol 1997; 115: 1537. 31.
Dalvin LA, Shields CL, Ancona-Lezama DA, et al. Combination of multimodal imaging features predictive of choroidal nevus transformation into melanoma. Br J Ophthalmol 2019; 103: 1441-1447. 32.
Shields CL, Dalvin LA, Yu MD, et al. Choroidal nevus transformation into melanoma per millimeter increment in thickness using multimodal imaging in 2355 cases: The 2019 Wendell L. Hughes Lecture. Retina 2019; 39: 1852-1860. 33.
Roelofs KA, O’Day R, Harby LA, et al. The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe? Cancers (Basel) 2020; 12: 1311. 34.
Al Harby L, Sagoo MS, O’Day R, et al. Distinguishing Choroidal Nevi from Melanomas Using the MOLES Algorithm: Evaluation in an Ocular Nevus Clinic. Ocul Oncol Pathol 2021; 7: 294-302. 35.
Damato BE. Can the MOLES acronym and scoring system improve the management of patients with melanocytic choroidal tumours? Eye 2023; 37: 830-836. 36.
Ching J, AlHarby L, Sagoo MS, Damato B. Is Tumour Thickness Measurement Required for MOLES Scoring of Melanocytic Choroidal Tumours? Ocul Oncol Pathol 2023; 9: 40-47. 37.
Barbagallo C, Stella M, Broggi G, et al. Genetics and RNA Regulation of Uveal Melanoma. Cancers 2023; 15: 775. 38.
Afshar AR, Damato BE, Stewart JM, et al. Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting Metastasis. Transl Vis Sci Technol. 2019; 8: 18. 39.
Robertson AG, Shih J, Yau C, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell 2017; 32: 204-220.e15. 40.
Scholes AGM, Damato BE, Nunn J, et al. Monosomy 3 in Uveal Melanoma: Correlation with Clinical and Histologic Predictors of Survival. Investig Opthalmology Vis Sci 2003; 44: 1008. 41.
Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev 2020; 90: 102091. 42.
Pilarski R, Byrne L, Carlo MI, Hanson H, Cebulla C, Abdel-Rahman M. BAP1 Tumor Predisposition Syndrome. 2016 Oct 13 [updated 2024 Dec 5]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A (eds.). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 43.
Bornfeld N, Prescher G, Becher R, et al. Prognostic implications of monosomy 3 in uveal melanoma. The Lancet 1996; 347: 1222- 1225. 44.
White VA, McNeil BK, Horsman DE. Acquired Homozygosity (Isodisomy) of Chromosome 3 in Uveal Melanoma. Cancer Genet Cytogenet 1998; 102: 40-45. 45.
Le Guin CHD, Metz KA, Lehmann N, et al. Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy. Biomarkers 2019; 24: 134-140. 46.
Martin M, Maßhöfer L, Temming P, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45: 933-936. 47.
Silva-Rodríguez P, Fernández-Díaz D, Bande M, et al. GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma. Cancers 2022; 14: 3066. 48.
Onken MD, Worley LA, Long MD, et al. Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma. Investig Opthalmology Vis Sci 2008; 49: 5230. 49.
van den Bosch T, Kilic E, Paridaens D, de Klein A. Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind? Dermatol Res Pract 2010; 2010: 1-13. 50.
Vader MJC, Madigan MC, Versluis M, et al. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer 2017; 117: 884-887. 51.
Staby KM, Gravdal K, Mørk SJ, et al. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma. Acta Ophthalmol (Copenh) 2018; 96: 31-38. 52.
Harbour JW, Onken MD, Roberson EDO, et al. Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas. Science 2010; 330: 1410-1413. 53.
Koopmans AE, Verdijk RM, Brouwer RWW, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol 2014; 27: 1321-1330. 54.
Uner OE, See TRO, Szalai E, et al. Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep 2021; 11: 8923. 55.
Golas MM, Sander B, Will CL, et al. Molecular Architecture of the Multiprotein Splicing Factor SF3b. Science 2003; 300: 980-984. 56.
Leeksma AC, Derks IAM, Kasem MH, et al. The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Front Oncol 2021; 10: 609409. 57.
Furney SJ, Pedersen M, Gentien D, et al. SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma. Cancer Discov 2013; 3: 1122-1129. 58.
Harbour JW, Roberson EDO, Anbunathan H, et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013; 45: 133-135. 59.
Thornton S, Coupland S, Olohan L, et al. Targeted Next-Generation Sequencing of 117 Routine Clinical Samples Provides Further Insights into the Molecular Landscape of Uveal Melanoma. Cancers 2020; 12: 1039. 60.
Yavuzyigitoglu S, Koopmans AE, Verdijk RM, et al. Uveal Melanomas with SF3B1 Mutations. Ophthalmology 2016; 123: 1118–1128. 61.
Field MG, Decatur CL, Kurtenbach S, et al. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res 2016; 22: 1234-1242. 62.
Chaudhuri J, Si K, Maitra U. Function of Eukaryotic Translation Initiation Factor 1A (eIF1A) (Formerly Called eIF-4C) in Initiation of Protein Synthesis. J Biol Chem 1997; 272: 7883-7891. 63.
Ewens KG, Kanetsky PA, Richards-Yutz J, et al. Chromosome 3 Status Combined With BAP1 and EIF1AX Mutation Profiles Are Associated With Metastasis in Uveal Melanoma. Investig Opthalmology Vis Sci 2014; 55: 5160. 64.
Küsters-Vandevelde HV, Creytens D, van Engen-van Grunsven AC, et al. SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas. Acta Neuropathol Commun 2016; 4: 5. 65.
Hunter SM, Anglesio MS, Ryland GL, et al.; Australian Ovarian Cancer Study Group. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 2015; 6: 37663-37677. 66.
Chien JL, Sioufi K, Surakiatchanukul T, et al. Choroidal nevus: a review of prevalence, features, genetics, risks, and outcomes. Curr Opin Ophthalmol 2017; 28: 228-237. 67.
Pandiani C, Béranger GE, Leclerc J, et al. Focus on cutaneous and uveal melanoma specificities. Genes Dev 2017; 31: 724-743. 68.
Brănișteanu DE, Porumb-Andrese E, Stărică A, et al. Differences and Similarities in Epidemiology and Risk Factors for Cutaneous and Uveal Melanoma. Medicina (Mex) 2023; 59: 943. 69.
Kvanta A, Seregard S, Kopp ED, et al. Choroidal Biopsies for Intraocular Tumors of Indeterminate Origin. Am J Ophthalmol 2005; 140: 1002-1006. 70.
Angi M, Kalirai H, Taktak A, et al. Prognostic biopsy of choroidal melanoma: an optimised surgical and laboratory approach. Br J Ophthalmol 2017; 101: 1143-1146. 71.
McCannel TA. Fine-needle aspiration biopsy in the management of choroidal melanoma. Curr Opin Ophthalmol 2013; 24: 262-266. 72.
Midena E, Bonaldi L, Parrozzani R, et al. In vivo Detection of Monosomy 3 in Eyes with Medium-Sized Uveal Melanoma using Transscleral Fine Needle Aspiration Biopsy. Eur J Ophthalmol 2006; 16: 422-425. 73.
Singh AD, Medina CA, Singh N, et al. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol 2016; 100: 456-462. 74.
Hussain RN, Damato B, Heimann H. Choroidal biopsies; a review and optimised approach. Eye 2023; 37: 900-906. 75.
Sen J, Groenewald C, Hiscott PS, et al. Transretinal Choroidal Tumor Biopsy with a 25-Gauge Vitrector. Ophthalmology 2006; 113: 1028-1031. 76.
Kim RS, Chevez-Barrios P, Bretana ME, et al. Histopathologic Analysis of Transvitreal Fine Needle Aspiration Biopsy Needle Tracts for Uveal Melanoma. Am J Ophthalmol 2017; 174: 9-16. 77.
Eide N, Walaas L. Fine‐needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: a review. Acta Ophthalmol (Copenh) 2009; 87: 588-601. 78.
Shields CL, Materin MA, Teixeira L, et al. Small Choroidal Melanoma with Chromosome 3 Monosomy on Fine-Needle Aspiration Biopsy. Ophthalmology 2007; 114: 1919-1924. 79.
Schefler AC, Gologorsky D, Marr BP, et al. Extraocular Extension of Uveal Melanoma After Fine-Needle Aspiration, Vitrectomy, and Open Biopsy. JAMA Ophthalmol 2013; 131: 1220. 80.
Bagger M, Smidt-Nielsen I, Andersen MK, et al. Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma. Ophthalmology 2018; 125: 1969-1976. 81.
Augsburger JJ, Shields JA, Folberg R, et al. Fine Needle Aspiration Biopsy in the Diagnosis of Intraocular Cancer. Ophthalmology 1985; 92: 39-49. 82.
Hussain RN, Damato B, Heimann H. Choroidal biopsies; a review and optimised approach. Eye 2023; 37: 900-906.
|
ENGLISH
